Beshay Zordoky, BSc Pharm, MSc, PhD, FAHA

Beshay Zordoky, BSc Pharm, MSc, PhD, FAHA is Professor of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy. His research accomplishments and scholarly expertise are centered on cardio-oncology, cardiovascular pharmacology, and therapy-induced aging, specifically aiming to mitigate the cardiovascular adverse effects and other long-term complications of cancer treatments. Dr. Zordoky has leveraged his extensive background in pharmaceutical sciences and cardiovascular research to publish over 65 peer-reviewed articles and has been recognized as a Fellow of the American Heart Association (FAHA). He continues his nationally and internationally-recognized research through his role as Principal Investigator for projects sponsored by the National Institutes of Health (NIH) and the American Cancer Society.

Awards & Recognition

• Fellow of the American Heart Association (FAHA)
• American Cancer Society Research Scholar
• Best Guest Editor Award, journal of Cardiovascular Toxicology 
• Top Viewed Article, JACC:CardioOncology Jan 2024 - Dec 2024
• Outstanding Junior Mentor Award, University of Minnesota Clinical and Translational Science Institute (CTSI)
• Special Merit Award for Excellence in Graduate Education, University of Minnesota College of Pharmacy
• Special Merit Award for Excellence in Service, University of Minnesota College of Pharmacy
• Special Merit Award for Excellence in Research, University of Minnesota College of Pharmacy
• Above and Beyond Award for Research Productivity, University of Minnesota College of Pharmacy

Professional Associations

American Heart Association

• Identifying the mechanisms of juvenile anthracycline-induced latent cardiotoxicity.
• Determining the role of cellular senescence in cancer treatment-induced cardiovascular toxicity.
• Defining sex-related differences in cardiovascular diseases.

• PHAR6531 - Spectrum of Chronic Care 
• PHAR6565 - Specialty Care & Systems Issues 
• ECP5620 - Drug Metabolism and Disposition 
• MICaB8013 - Translational Cancer Research

PubMed

Google Scholar

Integrated Omics Approach to Delineate the Mechanisms of Doxorubicin-Induced Cardiotoxicity. Dabour MS, Abdelgawad IY, Sadaf B, Daniel MR, Grant MKO, Blaes AH, Jacobson PA, Zordoky BN. Pharmaceuticals (Basel). 2026 Jan 29;19(2):234. doi: 10.3390/ph19020234.

Substrain-Dependent Differences in Doxorubicin-Induced Cardiotoxicity in Adult C57BL/6 Mice. Daniel MR, Grant MKO, Dabour MS, Razzoli M, Souza-Neto F, van Berlo JH, Bartolomucci A, Zordoky BN. Cardiovasc Toxicol. 2025 Dec 23;26(1):4. doi: 10.1007/s12012-025-10076-6.

Divergent immediate and delayed effects of juvenile exposure to doxorubicin on the thymus in C57BL/6 mice. George B, Dahlquist KJV, Grant MKO, Daniel MR, Smith DM, Ahlberg I, Sadak KT, Seelig D, Camell CD, Zordoky BN. Sci Rep. 2025 May 3;15(1):15557. doi: 10.1038/s41598-025-98617-5.

Canagliflozin differentially modulates carfilzomib-induced endoplasmic reticulum stress in multiple myeloma and endothelial cells. Dabour MS, George MY, Grant MKO, Zordoky BN. Arch Toxicol. 2025 Feb;99(2):729-744. doi: 10.1007/s00204-024-03913-0.

The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review. Dabour MS, George MY, Daniel MR, Blaes AH, Zordoky BN. JACC CardioOncol. 2024 Mar 12;6(2):159-182. doi: 10.1016/j.jaccao.2024.01.007.